Rovida Investment Management Ltd Grows Holdings in ASP Isotopes Inc. $ASPI

Rovida Investment Management Ltd grew its stake in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 28.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,100,000 shares of the company’s stock after acquiring an additional 900,000 shares during the period. ASP Isotopes makes up about 3.0% of Rovida Investment Management Ltd’s holdings, making the stock its 7th largest position. Rovida Investment Management Ltd’s holdings in ASP Isotopes were worth $21,894,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quantbot Technologies LP bought a new stake in shares of ASP Isotopes during the 3rd quarter worth about $34,000. BNP Paribas Financial Markets raised its position in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of ASP Isotopes during the 4th quarter worth about $48,000. Pictet Asset Management Holding SA bought a new stake in shares of ASP Isotopes during the 4th quarter worth about $61,000. Finally, Close Asset Management Ltd bought a new stake in shares of ASP Isotopes during the 3rd quarter worth about $72,000. 16.80% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Heather Kiessling sold 23,124 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $5.48, for a total value of $126,719.52. Following the sale, the chief financial officer directly owned 709,376 shares in the company, valued at $3,887,380.48. The trade was a 3.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Duncan Moore sold 11,642 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total transaction of $60,654.82. Following the completion of the sale, the director owned 1,044,928 shares in the company, valued at $5,444,074.88. The trade was a 1.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 90,704 shares of company stock worth $463,252 in the last ninety days. 14.40% of the stock is currently owned by corporate insiders.

ASP Isotopes Price Performance

NASDAQ ASPI opened at $7.78 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.39 and a quick ratio of 4.37. The company’s 50 day simple moving average is $5.23 and its 200 day simple moving average is $5.88. ASP Isotopes Inc. has a 12 month low of $3.92 and a 12 month high of $14.49. The company has a market capitalization of $979.50 million, a P/E ratio of -3.74 and a beta of 3.42.

ASP Isotopes (NASDAQ:ASPI) last released its earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The business had revenue of $8.36 million for the quarter, compared to the consensus estimate of $3.68 million.

Wall Street Analyst Weigh In

A number of research firms have commented on ASPI. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a research report on Tuesday, April 14th. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $13.00.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.